Novel retinoic acid receptor ligands in *Xenopus* embryos

Bruce Blumberg*, Jack Bolado, Jr.†, Fadila Derugin‡, A. Grey Craig§, Tanya A. Moreno*, Debabrata Chakravarti*, Richard A. Heyman¶, Jochen Buck∥, and Ronald M. Evans†**

*Gene Expression Laboratory, †Howard Hughes Medical Institute, and ‡Clayton Foundation Peptide Biology Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037; Department of Cell Biology, Ligand Pharmaceuticals, Inc., 9393 Towne Centre Drive, San Diego, CA 92121; §Memorial Sloan-Kettering Cancer Center, New York, NY 10021; and ¶Department of Pharmacology, Cornell University School of Medicine, New York, NY 10021.

Contributed by Ronald M. Evans, December 29, 1995

**Abstract**

Retinoids are a large family of natural and synthetic compounds related to vitamin A that have pleiotropic effects on body physiology, reproduction, immunity, and embryonic development. The diverse activities of retinoids are primarily mediated by two families of nuclear retinoic acid receptors, the RARs and RXRs. Retinoic acids are thought to be the only natural ligands for these receptors and are widely assumed to be the active principle of vitamin A. However, during an unbiased, bioactivity-guided fractionation of *Xenopus* embryos, we were unable to detect significant levels of all-trans or 9-cis retinoic acids. Instead, we found that the major bioactive retinoid in the *Xenopus* egg and early embryo is 4-oxoretinaldehyde, which is capable of binding to and transactivating RARs. In addition to its inherent activity, 4-oxoretinaldehyde appears to be a metabolic precursor of two other RAR ligands, 4-oxoretinol and 4-oxoretinol. The remarkable increase in activity of retinoidaldehyde and retinol as a consequence of 4-oxo derivatization suggests that this metabolic step could serve a critical regulatory function during embryogenesis.

4-oxoretinaldehyde (4-oxo-RAL) as the major bioactive retinoid in the *Xenopus* egg and early embryo. In addition to being able to bind to and transactivate RARs, 4-oxo-RAL appears to be a metabolic precursor of two other RAR ligands, 4-oxoretinol (4-oxo-ROL) (7) and 4-oxoretinol (4-oxo-ROL) (10). Taken together with the nearly complete lack of all-trans and 9-cis RAs during early development, our results suggest that the oxoretinoids may be the primary retinoids functioning during early *Xenopus* development and that the spectrum of natural bioactive retinoids is much broader than had been suspected. Previous studies have suggested the importance of isomerization to create novel retinoid acid derivatives. This work shows that selective modification of the cyclohexenyl ring may convert retinol and retinal to bioactive hormones.

**Methods**

Retinoid Extraction, Fractionation, and Identification. All extraction and other experiments with retinoids were carried out using subdued amber illumination ([Sylvania Electric Products](https://www.sylvania.com)) F40GO bulb, minimizing exposure to oxygen and heat where possible.

*Xenopus* ovaries or embryos were homogenized in 4 vol of H$_2$O, extracted with 0.6 vol of a 1:1 mixture of acetonitrile/1-butanol (containing 10$^{-4}$ M butylated hydroxytoluene as an antioxidant), and 0.3 vol of saturated K$_2$HPO$_4$ (11). After centrifugation, the organic phase was analyzed by HPLC. Successive aliquots of the organic phase were loaded onto reversed phase C18 columns equilibrated in buffer A (0.1 M ammonium acetate, pH 6.4) attached to a Waters model 600E pump with a Waters model 996 photodiode array detector; data were collected at 1 spectrum per second with a 2.4-nm resolution between 200 and 600 nm. The analytical HPLC profile shown in Fig. 1.4 was obtained with a Vydac (Hesperia, CA) C18 column (201TP54, 0.46 × 25 cm) using a flow of 1.5 ml/min and a mobile phase of 60% buffer A/40% acetonitrile at 1 min, proceeding linearly to 32% buffer A/68% acetonitrile at 35 min, and then to 100% acetonitrile at 36 min (method 1). The major bioactivity in fractions 30–52 coeluted with a compound having a $A_{284}$ of 384 nm. For scale up, ovaries from 10 frogs were pooled and extracted as above. Successive 2-ml aliquots of the organic extract from three frogs were loaded onto a 2.2 × 25 cm Vydac C18 column (218TP) equilibrated in buffer A. Elution was carried out with a flow rate of 8 ml/min and a linear gradient profile of buffer A/methanol/dichloromethane; 100% buffer A changing to 30% buffer A/70% methanol at 5 min, increasing to 100% methanol at 35 min, and holding at 100% to 40 min, then continuing to 60%

**Abbreviations:** RAL, retinaldehyde; ROL, retinol; RA, retinoic acid; RAR, retinoic acid receptor; RXR, 9-cis RAR; 4-oxo-RAL, 4-oxoretinaldehyde; 4-oxo-ROL, 4-oxoretinol; 4-oxo-RA, 4-oxoretinol; DAI, dorsoanterior index; h, human; X, Xenopus; tRA, all-trans-RA.

---

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
mixed fractions 30-33 from 16 and 20-22), early gastrula (stage 11), early neurula (stage 13-14), mid neurula (stage 16-18), late neurula (stage 20-22), and tailbud (stage 26-28). The total amount of each retinoid from a particular stage was normalized to the number of embryos and expressed as pg per embryo.

cotransfection assay. Fractions from 17 to 20 min were pooled and fractionated on an analytical Vydc C18 column (201TP54, 0.46 × 25 cm) developed isocratically with 35% buffer A/27% MeOH/38% acetonitrile (method 4). Fractions (15 sec) were collected and aliquots were tested in the cotransfection assay. Active fractions between 10 and 12 min were pooled and refractionated on the same column with the same mobile phase except that buffer and butylated hydroxytoluene were omitted. The pure compound has a retention time of 11.4 min.

The high-resolution mass spectrum was measured on a JEOL model JMS-HX100 double-focusing mass spectrometer using a 70-eV electron impact ionization source, 180°C ion source temperature, ~40°C direct insertion probe temperature, perfluorokerosene as reference, and a resolution of 5000.

**Retinoid Quantitation.** Pools of 1000 embryos were collected, quick frozen, and stored at ~70°C until use. Embryos were thawed, homogenized in 8 ml of H2O, and extracted with 5 ml of acetonitrile/1-butanol and 2.5 ml of saturated K2HPO4. After centrifugation, the organic phase was loaded onto the
semipreparative C18 column equilibrated in buffer A and eluted at 2 ml/min with the following gradient profile: 100% buffer A to 25% buffer A/75% methanol at 2.5 min, linearly increasing to 100% methanol at 20 min, then changing to 60% methanol/40% buffer D (50% methanol/50% CHCl3) at 27.5 min and then to 100% buffer D at 30 min. Fractions between 14 and 26 min were pooled and refraccionated on the analytical C18 column using gradient 1. Fractions (30 sec) were collected beginning at 10 min, dried, and resuspended in 25 μl of methanol. Fractions were subsequently tested in their entirety for bioactivity using the cotransfection assay (described below).

For retinoid quantitation, chromatograms were extracted from the three-dimensional photodiode array contour plots at the λmax for each compound in this solvent system, and areas under the peaks were calculated using Waters MILLENNIUM CHROMATOGRAPHY MANAGER software. Absorbance was calculated from the integrated area using the molar extinction coefficient for each compound: 4-oxo-ROL ε365 = 34,000, 4-oxo-RAL ε365 = 42,500, and 4-oxo-RA ε360 = 58,220 M⁻¹ cm⁻¹.

Cell Culture and Transfection. CV-1 cells were maintained in DMEM containing 10% resin-charcoal stripped calf bovine serum. Delipidated serum was prepared by stirring heat-inactivated serum for 3 hr with an equal volume of n-heptane (12) and then allowing the phases to separate. The serum phase was then re-extracted as above with n-heptane and the aqueous phase collected. The heptane treated serum was then resin-charcoal extracted twice and stored at 4°C until use. This treatment removed 99% of serum retinol; other retinoids were undetectable by HPLC. Liposome-mediated transient transfections were performed using DOTAP reagent (Boehringer Mannheim) at a concentration of 5 μg/ml in DMEM containing 10% delipidated fetal bovine serum in 96-well format using a Beckman model Biomek 1000 laboratory workstation. In a typical experiment, cells were plated at a density of 5 × 10⁴ cells per well. The next day, DNA/DOTAP mixture was added in the ratios 10 ng receptor expression plasmid/50 ng of reporter plasmid/40 ng of CMX-β-galactosidase control plasmid per well. After 12–18 hr, the cells were washed and fresh DMEM/10% delipidated serum containing HPLC fractions or retinoids was added in triplicate such that the solvent volume was <2%. After another 24-hr incubation, the cells were lysed and luciferase reporter gene assays and β-galactosidase transfection control assays were done as described (13). Reporter gene expression was normalized to the β-galactosidase transfection control and expressed as relative light units per OD of β-galactosidase activity per minute to allow comparison of inductions between experiments.

pCMX-GAL-hRARβ and pCMX-GAL-hRARγ were prepared by cloning amino acids 147–448 of hRARβ or amino acids 156–454 of hRARγ into pCMX-GAL4 (14).

4-oxo-RAL and 4-oxo-ROL were synthesized as described (10, 15). 4-oxo-all-trans-RA was a gift of Hoffmann-La Roche (to J. Buck) and 3,4-didehydro-RA was a gift of Dr. David Mangelsdorf (University of Texas Southwestern Medical School, Dallas). Other retinoids were purchased from Sigma. All retinoids were stored in amber glass vials as 10⁻³ M ethanolic solutions containing 10⁻⁴ M butylated hydroxytoluene at −70°C. Before

![Figure 3](image-url)
storage, the vials were blanketed with argon (ultrapure oxygen-free gas).

Protease Protection and Ligand Binding. 35S-labeled xRARα (x, Xenopus) was transcribed and translated in vitro using the TNT reticulocyte lysate system (Promega) and [35S]methionine (New England Nuclear). Aliquots of protein were incubated with candidate ligands or solvent control on ice for 30 min and then at 20°C for 10 min. Typically, 5 μL of protein–ligand mixture was added to 5 μL of trypsin (Boehringer Mannheim) diluted in H2O. Incubation was carried out on ice for 7 min and then at 30°C for 12 min. Digestion was terminated by the addition of 10 μL of SDS/loading buffer and boiling for 10 min. The samples were loaded onto an SDS/12% polyacrylamide gel and electrophoresed at 100 V for 15 min followed by 200 V for 25 min. Gels were fixed in 30% methanol/10% acetic acid, sprayed with En3Hance (New England Nuclear), dried, and exposed to x-ray film.

In vitro ligand binding assays used baculovirus-expressed hRARα, β, -γ, and all-trans-[^3H]RA or 9-cis[^3H]RA and were carried out as described (16).

RESULTS AND DISCUSSION

Lipid extracts were prepared from several thousand mixed-stage embryos and analyzed by reversed-phase HPLC with photodiode array detection between 200 and 600 nm. Fractions were tested for RAR and RXR agonist activity using the cotransfection assay (13). As shown in Fig. 1A, we showed several RAR-specific activities that had UV spectra and elution times different from known standard retinoids. The major active fractions 30–32 (Fig. 1A) coeluted with a compound having an absorption spectrum maximum at 384 nm, characteristic of a retinaldehyde. Because adult ovaries contained these same fractions, we used them to scale up the production of this retinoid, and to purify it to homogeneity. The high-resolution mass spectrum gave an observed m/z value of 298.1958, calculated for C30H32O2 = 298.1933, indicating that this compound has two hydrogen atoms less and one oxygen atom more than retinaldehyde. The molecular formula is consistent with 4-oxo-RAL. Indeed, the low-resolution electron impact mass spectrum (Fig. 1B) exhibits, in addition to the molecular peak m/z 298, a fragment at m/z 269 corresponding to the loss of a CHO end group. Furthermore, these data exclude 3,4-ddRA, which has the same molecular mass.

Table 1. Teratogenic effects of retinoids in Xenopus embryos

<table>
<thead>
<tr>
<th>Retinoid</th>
<th>DAI in presence of retinoid</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10−5 M</td>
</tr>
<tr>
<td>4-oxo-RAL</td>
<td>ND</td>
</tr>
<tr>
<td>RAL</td>
<td>2.7</td>
</tr>
<tr>
<td>4-oxo-ROL</td>
<td>ND</td>
</tr>
<tr>
<td>ROL</td>
<td>4.2</td>
</tr>
<tr>
<td>tRA</td>
<td>1.0</td>
</tr>
<tr>
<td>9RA</td>
<td>1.0</td>
</tr>
<tr>
<td>4-oxo-tRA</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Embryos were treated in groups of 20 at the early blastula stage (stage 8) with retinoids diluted in 20 ml of 0.1× modified Barth’s saline and allowed to develop until stage 13 at 18°C. The embryos were subsequently washed three times in 0.1× MBS and incubated until stage 38–40 when they were fixed and scored for development using the DAI (24) as modified for RA by Sive et al. (25). Briefly, a DAI of 5 is normal; DAI 4.5, reduced forehead; DAI 4, reduced forehead, slightly cyclopic; DAI 3.5, cyclopic; DAI 3.0, extremely cyclopic, normal or reduced cement gland; DAI 2.5, no eye pigment, some cement gland present; DAI 2.0, no cement gland, beating heart and otic vesicle present; DAI 1.0, no beating heart, no otic vesicle; DAI 0, completely ventralized; and DAI 10, completely dorsalized. Surviving embryos showing normal gastrulation were scored and averaged to yield the values shown. The number of surviving embryos used for scoring is shown in parenthesis. ND, not determined.

*Significant death also observed.

Table 2. Oxoretinoids compete for binding to RARs

<table>
<thead>
<tr>
<th>Retinoid</th>
<th>IC50, nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-oxo-RAL</td>
<td>35,000</td>
</tr>
<tr>
<td>RAL</td>
<td>NC</td>
</tr>
<tr>
<td>4-oxo-ROL</td>
<td>15,000</td>
</tr>
<tr>
<td>ROL</td>
<td>NC</td>
</tr>
<tr>
<td>4-oxo-RA</td>
<td>29</td>
</tr>
<tr>
<td>tRA</td>
<td>24</td>
</tr>
</tbody>
</table>

IC50 values shown are the concentrations at which 50% of prebound 3H-all-trans RA is displaced from baculovirus-expressed human RARs. NC, no competition observed.

**Oxoretinoids**

formula, but whose absorption spectrum (λmax = 366 nm) and retention time are different (Fig. 1C). Synthetic 4-oxo-RAL matches our embryonic activity in retention time, absorption spectrum mass, and biological activity (Fig. 1A and C). The identification of the major embryonic RAR agonist as all-trans-4-oxo-RAL raised the issue of whether it was acting directly, by conversion to the previously described 4-oxo-RA (7) or to another derivative.

To address this question, we first determined which oxoretinoids were present at important developmental stages. Lipid extracts were prepared from pools of 1000 staged embryos and fractionated first by semipreparative and then by analytical reversed phase chromatography using C18 columns and an acetonitrile/ammonium acetate gradient. Under these conditions, baseline resolution of a complex mixture of retinoid standards is achieved in 45 min (Fig. 24). Fractions from the analytical column were collected and tested in their entirety for agonist activity. Activities were correlated with the elution profile and UV spectrum of the fractions to unambiguously identify RAR agonists. The use of photodiode array detection between 200 and 600 nm allowed individual chromatograms to be produced at the λmax for each compound of interest and calculation of concentration from the extinction coefficients and absorbance values. The limit of detection in this system is 0.5 ng of RA with the generation of an ambiguous absorption spectrum and 0.1 ng without. The results are summarized in Fig. 2B. Levels of 4-oxo-ROL, 4-oxo-RAL, and 4-oxo-RA differ during early development, implying specific functions for each. 4-oxo-RAL is present at high levels in the egg, reaches a maximum at gastrulation, decreases throughout neurulation, and then increases sharply during the tailbud stages. We could also detect significant quantities of 4-hydroxy-RAL, a potential precursor for 4-oxo-RAL, throughout early development, at levels parallel to those of 4-oxo-RAL (data not shown).

In contrast, 4-oxo-RA levels are minimal when 4-oxo-RAL is maximal at gastrulation and then later increase slightly during tailbud stages; moreover, the absolute levels are only about one-third those of 4-oxo-RAL (Fig. 2B). 4-oxo-ROL shows a striking change during development in that it is undetectable before neurulation and then steadily increases thereafter. The differential temporal distribution of the three major oxoretinoids and the lack of a simple correlation between their levels argues against conversion to the 4-oxo-RA as generating the only, or even the major, embryonic RAR agonist. This is especially significant because we could not reproducibly detect all-trans-RA or 9-cis-RA, even with this highly sensitive detection system, during the same developmental time period. Although, as previously described (8, 9), there were compounds with UV absorbance at 350 nm that comigrated with authentic all-trans and 9-cis RAs, photodiode array analysis showed them to have UV absorption spectra distinct from all-trans and 9-cis RAs (data not shown).

Because the temporal and spatial patterns of xRAR and xRXR subtypes and isomers differ during early Xenopus
development (18–21), it was of interest to know whether the oxoretinoids showed any differences in their ability to activate these receptors. Fig. 3 shows a representative profile for the transcriptional response of hRARα, -β, and -γ (Fig. 3 A–C) and mouse RXRα, -β, and -γ (Fig. 3 D–F) to different doses of retinoids. 4-oxo-RAL and 4-oxo-ROL were typically much better RAR activators than RAL and ROL, respectively (Fig. 3 A–C). RARs were activated ~10-fold better by 4-oxo-ROL than by ROL and by 4-oxo-RAL than by RAL. Conversion of 4-oxo-RAL and 4-oxo-ROL to 4-oxo-RA is an improbable explanation for the observed activity since the potency of these three compounds is nearly the same. In fact, at lower doses (10^{-8} to 10^{-7} M) 4-oxo-RAL is typically more potent. In addition, all-trans RA is a more potent activator than 4-oxo-RA whereas 4-oxo-RAL is a more potent activator than RAL. If the aldehydes act primarily by conversion to RAs, then one would expect RAL to be more potent than 4-oxo-RAL because all-trans RA is a much better activator at all concentrations than is 4-oxo-RA; moreover, we would expect to see a shift in the dose-response reflective of the need for conversion as is the case for ROL and RAL. Rather, we believe that the strong activation elicited by 4-oxo-RAL reflects primarily native activity and secondarily its potential to be converted into two other efficient activators, 4-oxo-ROL and 4-oxo-RA.

The spectrum of oxoretinoid activity is markedly different on the RXRs than the RARs. As shown in Fig. 3 D–F, all-trans-4-oxo-ROL and ROL are inactive on all three RXRs whereas 4-oxo-RAL and RAL are weak activators; all-trans RA and 4-oxo-RA are the most potent activators. Gudas and colleagues (10) have obtained similar results with all-trans-4-oxo-ROL. Interestingly, 9-cis-4-oxo-ROL is a weak RXR activator (Fig. 3 D–F) whereas 13-cis-4-oxo-ROL was inactive on RXR (data not shown). All three oxo-ROL isomers were equally active on the RARs (Fig. 3 A–C and data not shown). Again, these results are not simply explained by conversion of 4-oxo-ROL and RAL to 4-oxo-RA.

The effect of the oxoretinoids on Xenopus embryos paralleled the activation assays described above. Xenopus embryos were treated at the early blastula stage over a range of concentrations with oxoretinoids or nonoxoretinoids and then allowed to develop until stage 40. When scored for the extent of anterior development using the dorsoanterior index (DAI) (24), it was again observed that 4-oxo-ROL and 4-oxo-RAL were much more potent than RAL or ROL in perturbing normal development (Table 1). Taken together with the receptor transactivation assays, these results suggest that 4-oxo-RAL and 4-oxo-ROL are good agonists, and are likely to be biologically relevant ligands for the xRARs.

The binding of 4-oxo-RAL to RARs and RXRs was determined using purified hRARα, -β, -γ, and hRXRα. We measured the ability of unlabeled oxoretinoids to displace prebound [-3H]RAs in standard competition binding assays (16). In accord with the activation data, 4-oxo-RAL and 4-oxo-ROL were unable to compete with 9-cis-[3H]RA for binding to hRXRα (data not shown) whereas both competed with all-trans-[3H]RA for binding to hRARα, -β, and -γ (Table 2). We note that the amount of oxoretinoids required to displace 50% of all-trans-[3H]RA binding was several hundred-fold higher.
than the amount required for significant receptor activation (Fig. 3). However, for reasons that are not obvious, receptor activation profiles occur over an exceptionally large range, yielding activation curves substantially more sensitive than predicted by the binding data. These data suggest either that 4-oxo-RAL and 4-oxo-ROL bind to the receptors somewhat differently in vitro than in vivo or that conversion to a more active form such as 4-oxo-RA is required for the observed activation.

To further investigate this discrepancy between binding and activation, we used a protease protection assay (26, 27). This assay measures the ability of a compound to alter receptor three-dimensional structure and thus its susceptibility to limited proteolysis. The susceptibility to protease cleavage has been shown to be modified by ligand binding. 35S-labeled, in vitro transcribed, translated xRARs was incubated with increasing concentrations of various proteases in the presence of solvent carrier or retinoids. As shown in Fig. 4, 4-oxo-ROL and 4-oxo-RA provide similar degrees of protection from trypsin digestion as does all-trans RA and much greater protection than does RAL. This result is both consistent with the activation assays shown in Fig. 3 and ligand binding data shown in Table 2 and further supports the idea that 4-oxo-ROL can directly bind to the RARs, resulting in transcriptional activation. The rank order of potency for activation is similar to the protease cleavage and displacement binding data. The discrepancy between the large amount of 4-oxo-ROL compared with RA required to displace prebound all-trans RA from RAR and the approximately equal amounts of 4-oxo-ROL and RA required to protect the receptors from limited proteolysis can be explained by a high off rate for binding to the receptors. The protease protection assays are always done under equilibrium conditions and would be relatively insensitive to high off rates, whereas the last step of the displacement assay, and of most other direct binding assays, is the separation of free from receptor-bound retinoids in which a fast off rate may be reflected in the binding results. Furthermore, the protease protection assay measures alteration of the receptor’s three-dimensional structure, which may be a more reliable indicator of ability to activate than binding (27). Thus, a key feature of the 4-oxo series of retinoids is their ability to achieve receptor binding at low concentrations (≈10−8 M) in the absence of the terminal carboxylic acid moiety previously thought to be essential for high affinity binding of retinoids to RARs and RXRs (1).

While there has been ongoing controversy regarding the precise role of endogenous RA in Xenopus development, the potent biological effects of exogenously added retinoids together with the variety of retinoids present during development strongly supports the idea that retinoids play key roles in embryogenesis. As a requisite step in understanding the role of retinoids during Xenopus development, we sought to identify the endogenous compounds capable of activating xRARs and xRXRs, the primary mediators of RA’s developmental effects. We identified the novel RAR ligands 4-oxo-ROL and 4-oxo-ROL in addition to the previously described 4-oxo-RA (7). The oxoretinoids constitute the majority of the embryonic RAR agonists that, taken together with the nearly complete lack of all-trans 9-cis RA, identifies 4-oxo-ROL, 4-oxo-ROL, and 4-oxo-RA as the predominant bioactive retinoids during early Xenopus development. Rather than representing degradative products of “normal” retinoids, we propose that members of the 4-oxo series should be considered authentic signaling molecules used for discrete purposes during development. Thus, we infer that oxidative enzymes associated with the synthesis and metabolism of these bioactive retinoids will be important regulatory targets during development and that their identification will be critical to understanding the role of retinoids in pattern formation.

We thank Drs. David Mangelsdorf and John W. R. Schware for comments on the manuscript; Dale Mais, Karen Flatter, and Mike Ming for assistance with ligand binding assays; and Henry U. Juguilon for assistance with tissue culture. R. M. E. is an Investigator of the Howard Hughes Medical Institute at the Salk Institute for Biological Studies (La Jolla). This work was supported by National Institutes of Health Grants HD-27183 and CA-54418 to R. M. E., Grant DK-44841 to J. Buck, Grant GM-47599 to F. D. & M., and American Cancer Society Grant DB-36 (B.B.), and in part by the Foundation for Medical Research (A.G.C.). J. Buck is a Pew Scholar in the Biomedical Sciences. D. C. is a postdoctoral fellow of the Jane Coffin Childs Memorial Fund for Medical Research.


